Navigating Advanced Disease and Long-Term Quality of Life
At a Glance
Advanced VPS13A disease care focuses on comfort, safety, and quality of life. Swallowing, seizures, mood, heart health, caregiver needs, advance planning, and family genetic counseling should be addressed with an individualized care team.
Navigating the advanced stages of VPS13A disease requires a shift in focus from finding answers to maximizing comfort and safety. While this is a progressive condition, many symptoms can be managed effectively through specialized supportive care and nursing, which research shows can significantly improve your quality of life [1][2].
Understanding the Long-Term Trajectory
Because VPS13A disease is so rare, it is difficult to predict an exact timeline for any one person. One small retrospective review of 52 cases found that the average time from diagnosis to the end of life was about 11 years [3]. However, this number cannot predict an individual’s course; it is strongly affected by diagnostic delay and ascertainment, and because diagnosis is often delayed, diagnosis-based survival is not the same as time from first symptoms [4][5]. Have an individualized prognosis discussion with your treating team.
The goal of advanced care is to monitor and prevent the most common complications:
- Respiratory Health: Pneumonia is one of the most frequently reported causes of death [3]. This is often related to dysphagia (swallowing difficulty), where food or liquid accidentally enters the lungs [6]. Proactive swallowing assessments and diet modifications may help reduce this risk, though they cannot entirely eliminate aspiration [6][7].
- Cardiac Monitoring: While severe cardiac disease is more strongly associated with the look-alike condition McLeod syndrome, some patients with VPS13A develop reported mild heart issues, such as a slightly weakened heart muscle [8]. Cardiac monitoring (like an EKG or echocardiogram) should be individualized based on your symptoms, exam, family history, or diagnostic uncertainty [8][3].
- Seizure Control: Seizures can become more frequent or harder to treat as the disease progresses [9][10]. Ensuring your medications are adjusted as your body changes is essential for safety [9][3].
Mental Health and Suicidality
Psychiatric and cognitive symptoms are common but variable; one cohort reported them in over 97% of patients [11]. These can include depression, anxiety, and changes in behavior [11].
Critically, one retrospective cohort found that roughly 10% of patients with this diagnosis experience significant thoughts of self-harm or suicide [3]. This makes mental health support just as important as physical therapy. If you or a loved one feels hopeless or experiences a major change in mood, it should be addressed immediately with your care team [3].
Safety Instruction: If someone may act on suicidal thoughts, has a plan, or cannot stay safe, contact local emergency services or a crisis service immediately, do not leave the person alone, and involve a trusted support person.
Palliative Care: Not Just for the End
Palliative care is specialized medical care focused on providing relief from the symptoms and stress of a serious illness [2]. It is not the same as hospice; you can receive palliative care at any stage of your journey.
- Symptom Relief: Palliative specialists are experts in managing complex pain, severe muscle spasms (dystonia), and the distress caused by involuntary movements [1][2]. Include practical advance-care-planning topics such as hospitalization preferences, emergency treatment, communication support, and goals around oral versus tube feeding.
- Caregiver Support: Caring for someone with advanced VPS13A disease is physically and emotionally demanding. Palliative care teams provide support for caregivers, helping to navigate “burnout” and connecting families with home-care resources or respite programs [1].
Family Planning and Relatives
Since this is an autosomal recessive condition, siblings of an affected person have a 25% (1 in 4) chance at conception of also having the disease when both parents are carriers. An already-unaffected sibling has a different residual carrier risk, and the risk to children of an affected person depends on the other parent [12].
- Targeted Testing: If you have had genetic testing that identified your established familial pathogenic variants, your relatives can undergo “targeted testing” to see if they are carriers or are also affected [13][14].
- Counseling: Because family members with the same mutation can have very different symptoms, a genetic counselor is the best person to help relatives interpret their results and understand their own risks for the future [15][14].
While the road ahead is challenging, you do not have to walk it alone. Symptom-focused care, a strong support network, and an early focus on quality of life can help you and your family maintain dignity and comfort throughout the journey.
Common questions in this guide
What should care focus on when VPS13A disease becomes advanced?
What is the long-term outlook for someone with VPS13A disease?
When can palliative care help with chorea-acanthocytosis?
What can help with swallowing problems in advanced VPS13A disease?
How should seizures and possible heart problems be monitored?
What immediate action is needed if someone with VPS13A disease has suicidal thoughts?
How can relatives find out their genetic risk for VPS13A disease?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Choreoacanthocytosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific symptoms—such as weight loss, persistent coughing, or frequent seizures—should signal that it is time for a formal palliative care or hospice consultation?
- 2.Can you help us create an 'advance care plan' that outlines my preferences for feeding tubes (PEG) and hospitalizations if my condition progresses?
- 3.Given the risk of cardiac involvement, how often should we be doing EKGs or echocardiograms based on my specific symptoms?
- 4.Are there local resources or respite care programs you recommend to help prevent caregiver burnout?
- 5.If a sibling or relative wants to be tested, what is the exact process for 'targeted testing' based on my specific genetic mutations?
References
References (15)
- 1
Management of Neuroacanthocytosis Syndromes.
Walker RH
Tremor and other hyperkinetic movements (New York, N.Y.) 2015; (5()):346 doi:10.7916/D8W66K48.
PMID: 26504667 - 2
Two case reports of chorea-acanthocytosis and review of literature.
Huang S, Zhang J, Tao M, et al.
European journal of medical research 2022; (27(1)):22 doi:10.1186/s40001-022-00646-7.
PMID: 35130982 - 3
Life expectancy and mortality in chorea-acanthocytosis and McLeod syndrome.
Walker RH, Miranda M, Jung HH, Danek A
Parkinsonism & related disorders 2019; (60()):158-161 doi:10.1016/j.parkreldis.2018.09.003.
PMID: 30245172 - 4
Clinical variability of neuroacanthocytosis syndromes-a series of six patients with long follow-up.
Dulski J, Sołtan W, Schinwelski M, et al.
Clinical neurology and neurosurgery 2016; (147()):78-83.
PMID: 27310290 - 5
Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease.
Peikert K, Glaß H, Federti E, et al.
Journal of personalized medicine 2021; (11(5)) doi:10.3390/jpm11050392.
PMID: 34068769 - 6
Clinico-genetic profile of case series of six Tamilian chorea-acanthocytosis families with VPS13A mutations from South India.
Saibaba J, Narayan SK, Sugumaran R, et al.
Parkinsonism & related disorders 2025; (137()):107917 doi:10.1016/j.parkreldis.2025.107917.
PMID: 40554046 - 7
Efficacy of Deep Brain Stimulation in a Patient with Genetically Confirmed Chorea-Acanthocytosis.
Richard A, Hsu J, Baum P, et al.
Case reports in neurology 2019; (11(2)):199-204 doi:10.1159/000500951.
PMID: 31543803 - 8
Cardiac manifestation is evident in chorea-acanthocytosis but different from McLeod syndrome.
Quick S, Heidrich FM, Winkler MV, et al.
Parkinsonism & related disorders 2021; (88()):90-95 doi:10.1016/j.parkreldis.2021.05.015.
PMID: 34153885 - 9
The Diverse Neuromuscular Spectrum of VPS13A Disease.
Buchberger A, Riedel E, Hackenberg M, et al.
Annals of clinical and translational neurology 2026; (13(1)):157-169 doi:10.1002/acn3.70198.
PMID: 41030128 - 10
Seizures as presenting and prominent symptom in chorea-acanthocytosis with c.2343del VPS13A gene mutation.
Benninger F, Afawi Z, Korczyn AD, et al.
Epilepsia 2016; (57(4)):549-56 doi:10.1111/epi.13318.
PMID: 26813249 - 11
Novel pathogenic VPS13A gene mutations in Japanese patients with chorea-acanthocytosis.
Nishida Y, Nakamura M, Urata Y, et al.
Neurology. Genetics 2019; (5(3)):e332 doi:10.1212/NXG.0000000000000332.
PMID: 31192303 - 12
Untangling the Thorns: Advances in the Neuroacanthocytosis Syndromes.
Walker RH
Journal of movement disorders 2015; (8(2)):41-54 doi:10.14802/jmd.15009.
PMID: 26090076 - 13
A Novel VPS13A Deletion in VPS13A Disease (Chorea-Acanthocytosis): A Case Report with Brief Literature Summary.
Perrone B, Mosca V, Pecoraro M, et al.
International journal of molecular sciences 2025; (26(23)) doi:10.3390/ijms262311521.
PMID: 41373679 - 14
Neuropathy-predominant and hyperkinetic-dystonic presentations in two siblings with a homozygous VPS13A variant: long-term follow-up and family-based clinical analysis.
Luo Y, Chen J, Ling T, et al.
BMC neurology 2026; doi:10.1186/s12883-026-05170-3.
PMID: 42426634 - 15
[Phenotypic variability in sisters with VPS13A disease (chorea-acanthocytosis)].
Oner OG, Varoglu AO
Ideggyogyaszati szemle 2025; (78(1-2)):69-72 doi:10.18071/isz.78.0069.
PMID: 40042450
This page is for informational purposes only and does not constitute medical advice. Your neurologist, genetic counselor, and palliative care team should tailor recommendations to your symptoms, safety needs, and goals.